Tu
Turning Point (BMS)
San Diego CAFounded 2013300 employees
Private CapbiotechAcquiredOncology
Platform: Next-gen ALK
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| TUR-3071 | TUR-3071 | NDA/BLA | 1 | GIP-R | PAHRB | ||
| Voxafotisoran | TUR-7130 | Phase 2 | 1 | MDM2 | DLBCLNB | ||
| TUR-1584 | TUR-1584 | Phase 2/3 | 2 | FLT3 | GACSU | ||
| TUR-4034 | TUR-4034 | Phase 2/3 | 2 | C5 | Psoriasis |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)